A review of the use of latanoprost for glaucoma since its launch

Expert Opinion on Pharmacotherapy
Maurizio DigiuniLuca Rossetti

Abstract

Prostaglandins are increasingly used as first choice treatment for glaucoma because they are highly effective, lack relevant systemic side effects and require just once-daily administration. Latanoprost is an ester prodrug analog of prostaglandin F2α, which reduces intraocular pressure (IOP) by increasing uveoscleral outflow. Latanoprost 0.005% has received European and US approval as the first-line drug for reducing IOP in patients with open-angle glaucoma or ocular hypertension. Following the recent patent expiry for Xalatan®, a number of latanoprost generics have entered the glaucoma market. This review, achieved through PubMed and Medline research methods, describes the composition, pharmacokinetics, mode of action, efficacy, side effects and safety profile of latanoprost. Latanoprost was the first prostaglandin analog introduced in glaucoma management and it dramatically changed the market of the disease thanks to its efficacy and safety. Conjunctival hyperemia, which is commonly found after latanoprost use, is associated with a minor efficacy and duration of trabeculectomy; yet, from the ophthalmologist's perspective, this side effect seems largely counterbalanced by the high efficacy and safety of this compound. It is al...Continue Reading

References

Sep 1, 1989·Experimental Eye Research·B T Gabelt, P L Kaufman
Nov 1, 1984·Ophthalmology·M S PassoE M Van Buskirk
Aug 1, 1981·Clinical Pharmacology and Therapeutics·C A NaranjoD J Greenblatt
Jan 1, 1980·Clinical Pharmacokinetics·G AlvanG Widmark
Sep 1, 1994·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·H MietzG K Krieglstein
Apr 1, 1994·Prostaglandins, Leukotrienes, and Essential Fatty Acids·S BasuB Resul
Sep 15, 1994·American Journal of Ophthalmology·K SzerenyiP J McDonnell
Oct 1, 1996·The British Journal of Ophthalmology·R C GentileR Ritch
Feb 1, 1997·Survey of Ophthalmology·D F WoodwardA Ocklind
Feb 1, 1997·Survey of Ophthalmology·M DiestelhorstS Nagasubramanian
Sep 23, 1997·Archives of Ophthalmology·M Wand
Jan 24, 1998·American Journal of Ophthalmology·B PatelskaR Ritch
Apr 29, 1998·Journal of the American Optometric Association·I B Gaddie, D W Bennett
Apr 30, 1998·The Annals of Pharmacotherapy·A S Peak, B M Sutton
Jul 31, 1998·American Journal of Ophthalmology·R D FechtnerR Warwar

❮ Previous
Next ❯

Citations

Mar 16, 2013·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Bart A JessenMark Evans
Nov 25, 2014·Therapeutic Delivery·Elise V TaniguchiJoseph B Ciolino
Jun 29, 2013·Expert Opinion on Pharmacotherapy·Anastasios Gp KonstasMurat Irkec
Feb 6, 2016·Japanese Journal of Ophthalmology·Masahide YanagiAtsuki Fukushima
Jun 3, 2014·Annals of Dermatology·Ji Hye LeeSoo-Chan Kim
Oct 16, 2015·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Kuan-Hui Hsu, Anuj Chauhan
May 12, 2015·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Marta Rodriguez-AllerRobert Gurny
Jan 15, 2014·Bioorganic & Medicinal Chemistry Letters·Kengo SumiHiroyoshi Hidaka
Nov 10, 2016·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Romi YooByung Joo Cho
Apr 18, 2018·British Journal of Pharmacology·Peter G Klimko, Najam A Sharif
Sep 3, 2017·British Journal of Pharmacology·Sahar AwwadAlastair Lockwood
Oct 14, 2017·Ocular Immunology and Inflammation·M Reza Razeghinejad
Oct 31, 2019·Expert Opinion on Pharmacotherapy·Sapna SinhaReza M Razeghinejad
Aug 19, 2020·Clinical & Experimental Optometry : Journal of the Australian Optometrical Association·Jack PhuMichael Kalloniatis
Nov 5, 2014·European Journal of Ophthalmology·Ronit NesherDebora Kidron
Jan 9, 2017·International Ophthalmology·Usman JavaidNadeem Hafeez Butt
May 6, 2020·Vestnik oftalmologii·N I Kurysheva
May 10, 2020·Ophthalmology and Therapy·Maciej ŚwiątkiewiczPaweł Grieb
Mar 11, 2021·Clinical & Experimental Optometry : Journal of the Australian Optometrical Association·Henrietta WangJack Phu
May 31, 2020·Journal of Pharmaceutical and Biomedical Analysis·Paula M OliveiraGuilherme M Gelfuso

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.